Targeting BTK with Ibrutinib in
Relapsed Chronic Lymphocytic Leukemia; John C. Byrd, MD, The Ohio State University.
Auranofin is being evaluated by The Learning Collaborative as a treatment for
relapsed chronic lymphocytic leukemia (CLL).
Not exact matches
The targeted agent ibrutinib has shown a high response rate in both treatment - naive and previously treated,
relapsed, refractory
chronic lymphocytic leukemia (CLL) patients older than 65.
Venetoclax has durable clinical activity in patients with
relapsed / refractory
chronic lymphocytic leukemia whose disease progressed during or after ibrutinib therapy.
Relapsed or refractory
chronic lymphocytic leukemia and acute lymphoblastic
leukemia patients have shown durable responses of almost 2 years to a novel T - cell engineering technique developed at the University of Pennsylvania Perelman School of Medicine in Philadelphia.
Among patients with
relapsed / refractory
chronic lymphocytic leukemia, those who have higher stress related to their cancer experience at the start of treatment have worse psychological functioning during the first five months of treatment.
Findings suggest cancer - specific stress at treatment initiation may be a risk factor for poorer psychological functioning during treatment for patients with
relapsed / refractory
chronic lymphocytic leukemia.
To examine cancer - specific stress at treatment initiation as a predictor of psychological and physical functioning trajectories in patients with
relapsed / refractory
chronic lymphocytic leukemia during the first 5 months of treatment.
Little is known about the psychological and physical functioning of patients with
relapsed / refractory
chronic lymphocytic leukemia.